Cannabis Stocks to Put on Top of Your Radar-THC Therapeutics, Inc.

HENDERSON, NV / ACCESSWIRE / March 28, 2019 / Last week was a historic moment for the U.S. CBD industry, as CVS, the largest drugstore chain in US by total sales, began selling CBD products in select stores across the U.S. Eventually, big box retailers will be carrying CBD and cannabis products nationwide. Looking for other CBD & related products and companies offering them should be top of mind for investors.

One company developing an interesting product is THC Therapeutics, Inc. (THCT). They said that the US patent office has accepted ALL 20 claims for their herb dryer the dHydronator, which can reduce moisture content of cannabis to 10% in only 10-14 hours. The dHydronator® also destroys harmful surface contaminants & pathogens. Start your research today.

Today we are highlighting: THC Therapeutics, Inc. (THCT), Tilray, Inc. (TLRY), Terra Tech Corp (TRTC), Hexo Corp (HEXO), and Emerald Health Therapeutics (EMHTF).

THC Therapeutics, Inc. (THCT) (Market Cap: $97.100M; Share Price: $7.38) has developed a sanitizing herb dryer, The dHydronator®. Their laboratory-proven product is specifically designed for drying and sanitizing freshly harvested cannabis and herbs. THCT's product has been tested by two independent laboratories. The testing covered over 6 strains and 9 independent tests to confirm the findings.

As we mentioned earlier, the US patent office has accepted ALL 20 claims for The dHydronator®. This is big. Start your research today.

_______

Tilray, Inc. (TLRY) (Market Cap: $6.215B; Share Price: $64.85) acquired Manitoba Harvest from Compass Group Diversified Holdings (CODI). Under the terms of the Agreement, Tilray has acquired Manitoba Harvest on a cash and debt-free basis, for an aggregate maximum purchase price, including cash and class 2 Common Stock in the capital of Tilray ("Tilray Shares"), of C$419 million pending the achievement of certain milestones after the closing of the Transaction. Founded in 1998, Manitoba Harvest is the world's largest hemp food manufacturer and a leader in the natural foods industry. The deal will help Tilray tap into extensive US distribution network and upcoming line of CBD products of Manitoba Harvest.

_______

Terra Tech Corp. (TRTC) (Market Cap: $93.095M; Share Price: $0.99) announced the company has agreed to acquire the remaining stake in the Blüm Reno dispensary in Nevada. Under the agreement, Terra Tech will increase its stake in the Reno, Nev.-based dispensary to 100% from 50%. The acquisition includes the Blüm dispensary's cannabis licenses as well. Additionally, Terra Tech's ownership in the building which houses the dispensary will increase from 50% to 100%. The agreement is subject to the approval of the Nevada Department of Taxation. The company expects to receive response within 60 to 90 days.

_______

HEXO Corp. (HEXO) (Market Cap: $1.35B; Share Price: $6.40) announced in August 2018 that it is forming a joint venture with Molson Coors Canada (MCC). The company is partnering with HEXO, which'll likely be a top-10 producer by peak annual output. Molson Coors gets its foot in the door in a fast-growing industry, while giving HEXO the marketing leadership it needs. The joint venture, Truss, was formed in October 2018, led by former Molson Coors executive, Brett Vye, in the role of Chief Executive Officer. Vye reports to the Truss board of directors consisting of three members appointed by MCC and two members appointed by HEXO. Truss is structured as a standalone company with its own board of directors and independent management team. MCC has a 57.5% controlling interest with HEXO holding the remaining 42.5%.

_______

Emerald Health Therapeutics, Inc. (EMHTF) (Market Cap: $425.787M; Share Price: $3.0047) announced the launch of Verdélite Sciences Inc., a wholly-owned, Québec-based production subsidiary licensed by Health Canada. Formerly known as Agro-Biotech, Verdélite currently produces high-grade dried cannabis for medical and adult-use purposes.

Signed by

Priyanka Goel, CFA

Legal Disclaimer:

This article was written by Regal Consulting, LLC ("Regal Consulting"). Regal Consulting has agreed to a three-month term consulting agreement with THCT dated 2/14/18. The agreement calls for 50,000 restricted shares of THCT per month. All payments were made directly by THC Therapeutics, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. THCT was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.